Article in Molecular pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors at 3 institutions in 2 countries.
Douglas S MacPhersonDepartment of Chemistry, Hunter College of the City University of New York, 413 East 69th Street, New York, New York 10028, United States.ORCID 0000-0001-7973-3351
Dobeen HwangDepartment of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida 33458, United States.
Samantha M SarrettDepartment of Chemistry, Hunter College of the City University of New York, 413 East 69th Street, New York, New York 10028, United States.
Outi KeinänenDepartment of Chemistry, Hunter College of the City University of New York, 413 East 69th Street, New York, New York 10028, United States.ORCID 0000-0002-3939-6706
Cindy RodriguezDepartment of Chemistry, Hunter College of the City University of New York, 413 East 69th Street, New York, New York 10028, United States.
Christoph RaderDepartment of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida 33458, United States.
Brian M ZeglisDepartment of Chemistry, Hunter College of the City University of New York, 413 East 69th Street, New York, New York 10028, United States.ORCID 0000-0002-9091-744X
The Graduate Center, CUNY · USScripps Research Institute · USMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Novel Enediyne-Based Antibody-Drug Conjugates for CancersR01CA204484 · NCI · UNIVERSITY OF FLORIDA · PI Natarajan Muthusamy, Ben Shen · 2017 to 2026
$4.6M
Pretargeted Clinical Imaging of CA19.9 in Pancreatic CancerU01CA221046 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S., ZEGLIS, BRIAN MATTHEW · 2018 to 2022
$3.5M
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-TrastuzumabR01CA204167 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S., ULANER, GARY ALLAN · 2016 to 2020
$3.4M
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based TherapeuticsR01CA244327 · NCI · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2020 to 2024
$3.0M
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic LeukemiaR01CA174844 · NCI · UNIVERSITY OF FLORIDA · PI SHEN, BEN · 2018 to 2022
$3.0M
Novel Reagents for Rapid and Stable Thiol-Based BioconjugationsR01CA240963 · NCI · HUNTER COLLEGE · PI ZEGLIS, BRIAN MATTHEW · 2019 to 2023
$1.6M
The Ivis Spectrum CT for Pre-Clinical Oncology ResearchS10OD016207 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI ZANZONICO, PAT B · 2013 to 2013
$595k
SHARED INSTRUMENT: FOCUS MICROPET: CANCERS10RR020892 · NCRR · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 2005 to 2005
$499k
A PET Radiotracer for Diagnostic and Theranostics Imaging in Lyme DiseaseR21EB030275 · NIBIB · HUNTER COLLEGE · PI QIU, WEIGANG, ZEGLIS, BRIAN MATTHEW · 2020 to 2021
$429k
Harnessing PET to Study the In Vivo Fate and Health Effects of Micro- and NanoplasticsK99ES034053 · NIEHS · HUNTER COLLEGE · PI KEINAENEN, OUTI MARIA · 2022 to 2022
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate. · full record | OpenQuestion